


SRX3207

Cat. No.:	HY-136198		
CAS No.:	2254693-15-5		
Molecular Formula:	C ₂₉ H ₂₉ N ₇ O ₃ S		
Molecular Weight:	555.65		
Target:	Syk; PI3K		
Pathway:	Protein Tyrosine Kinase/RTK; PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 5 mg/mL (9.00 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.7997 mL	8.9985 mL	17.9969 mL
5 mM	0.3599 mL	1.7997 mL	3.5994 mL
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC₅₀ values of 10.7 nM and 861 nM for Syk and PI3K α, respectively. SRX3207 relieves tumor immunosuppression^{[1][2]}.

IC₅₀ & Target

Syk	PI3Kα	PI3Kδ	PI3Kγ
10.7 nM (IC ₅₀)	861 nM (IC ₅₀)	1280 nM (IC ₅₀)	11100 nM (IC ₅₀)
Zap70			
1300 nM (IC ₅₀)			

In Vitro

SRX3207 (10 μmol/L) is able to block p-AKT at concentration^[1].
 SRX3207 has sufficient solubility in water (43 μmol/L)^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SRX3207 (10 mg/kg, orally) increases antitumor immune response^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LLC or B16 or B16-OVA or CT26 (1×10^5) cells were injected subcutaneously into syngeneic mice ^[1] .
Dosage:	10 mg/kg.
Administration:	Orally, starting from day 10 when tumors reached 100 mm ³ until tumors were harvested on day 21.
Result:	Blocked phosphorylation of Syk at 348 site and Y525/526 site. Blocked immunosuppressive M Φ polarization. Blocked tumor growth and increased survival effectively.

REFERENCES

[1]. Shweta Joshi, et al. Macrophage Syk-PI3Ky Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.

[2]. Shweta Joshi, et al. Macrophage Syk-PI3Ky Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA